ENDRA Life Sciences (NDRA) Cash from Operations (2016 - 2026)

ENDRA Life Sciences (NDRA) has 11 years of Cash from Operations data on file, last reported at 1119650.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 1119650.0, up 13.42% year-over-year; the trailing twelve-month figure through Mar 2026 was 5009079.0 (up 23.52% YoY), and the FY2025 annual result was 5182558.0, up 29.97% from the prior year.
• Cash from Operations grew to 1119650.0 in Q1 2026 per NDRA's latest filing, from 1611711.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 1113715.0 in Q2 2025 and troughed at 3334982.0 in Q2 2022.
• A 5-year average of 2118876.53 and a median of 2144312.0 in 2024 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations slipped 19.13% in 2022, then jumped 46.54% in 2025.
• A 5-year view of Cash from Operations shows it stood at 3088689.0 in 2022, then gained by 29.6% to 2174578.0 in 2023, then soared by 30.3% to 1515705.0 in 2024, then retreated by 6.33% to 1611711.0 in 2025, then jumped by 30.53% to 1119650.0 in 2026.
• Business Quant data shows NDRA's Cash from Operations at 1119650.0 in Q1 2026, 1611711.0 in Q4 2025, and 1164003.0 in Q3 2025.